AR078734A1 - Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones - Google Patents

Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones

Info

Publication number
AR078734A1
AR078734A1 ARP100103877A ARP100103877A AR078734A1 AR 078734 A1 AR078734 A1 AR 078734A1 AR P100103877 A ARP100103877 A AR P100103877A AR P100103877 A ARP100103877 A AR P100103877A AR 078734 A1 AR078734 A1 AR 078734A1
Authority
AR
Argentina
Prior art keywords
ivig
body fluid
mammal
treatment
compositions
Prior art date
Application number
ARP100103877A
Other languages
English (en)
Original Assignee
Eiger Health Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Health Partners Llc filed Critical Eiger Health Partners Llc
Publication of AR078734A1 publication Critical patent/AR078734A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)

Abstract

Reivindicacion 1: Un método de mejora, tratamiento o prevencion de una enfermedad o trastorno asociados con una presencia de uno o varios autoanticuerpos en una circulacion de un mamífero, que comprende, en secuencia: (a) eliminacion de uno o varios de dichos autoanticuerpos de la circulacion de dicho mamífero; y (b) administracion a dicho mamífero de una preparacion intravenosa de inmunoglobulina (IVIG) que comprende al menos el 20% de inmunoglobulina 1 2 en una cantidad suficiente para restaurar el sistema inmune de dicho mamífero hasta homeostasis, en donde la preparacion de IVIG no contiene organismos virales detectables. Reivindicacion 31: Un método de purificacion de una inmunoglobulina intravenosa humana (IVIG) de un fluido corporal, en donde la IVIG resultante es apropiada para uso terapéutico, que comprende las etapas de: (a) remover uno o varios componentes de la vía de coagulacion del fluido corporal; (b) adicion de uno o varios alcoholes a fluido corporal para remover las proteínas no deseadas; (c) concentracion del fluido corporal en condiciones que evitan la activacion de la vía complementaria en el fluido corporal; y (d) tratamiento del fluido corporal para eliminar uno o varios contaminantes activos virales y microbianos; y (e) ensayo de la actividad de la IVIG al menos después de (d) para obtener una IVIG purificada del concentrado proteico plasmático, en donde la lVlG purificada es una lVlG altamente eficaz para el tratamiento de una o varias enfermedades o trastornos en un mamífero. Reivindicacion 43: Composiciones para mejorar, tratar o prevenir enfermedades o trastornos asociados con la presencia de uno o varios autoanticuerpos en la circulacion de un mamífero, en donde las composiciones contienen una o varias inmunoglobulinas obtenidas por medio del método de acuerdo con las reivindicaciones 31 a 42.
ARP100103877A 2009-10-22 2010-10-22 Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones AR078734A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25407209P 2009-10-22 2009-10-22
US30671810P 2010-02-22 2010-02-22

Publications (1)

Publication Number Publication Date
AR078734A1 true AR078734A1 (es) 2011-11-30

Family

ID=43898625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103877A AR078734A1 (es) 2009-10-22 2010-10-22 Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones

Country Status (8)

Country Link
US (2) US20110097344A1 (es)
EP (1) EP2490721A4 (es)
AR (1) AR078734A1 (es)
AU (1) AU2010310562A1 (es)
CA (1) CA2778158A1 (es)
RU (1) RU2012120620A (es)
TW (1) TW201125582A (es)
WO (1) WO2011050259A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
CN103257190B (zh) * 2013-04-15 2015-02-25 南京艾德凯腾生物医药有限责任公司 一种测定布洛芬/法莫替丁复方制剂含量的方法
CN106290657B (zh) * 2016-09-27 2018-07-06 海口南陆医药科技股份有限公司 一种用于检测地氯雷他定中杂质的方法
EP3431988B1 (en) * 2017-07-18 2021-03-10 CBmed GmbH Center for Biomarker Research in Medicine Method to determine the state of the humoral immune system in a patient
CA3115821A1 (en) * 2018-10-11 2020-04-16 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
CN111057153B (zh) * 2019-12-06 2021-09-07 广州康盛生物科技股份有限公司 一种免疫球蛋白结合蛋白及其制备方法和应用
CN111929394B (zh) * 2020-08-25 2022-11-08 北京和合医学诊断技术股份有限公司 华法林的检测方法
CN112763625B (zh) * 2020-12-30 2022-07-15 江苏正济药业股份有限公司 一种法莫替丁及其有关物质的检测方法
WO2023235428A1 (en) 2022-05-31 2023-12-07 Lyfspn, Inc. Compositions and methods for plasmapheresis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
AU2006292132A1 (en) * 2005-09-19 2007-03-29 Palingen, Inc. Treatment of B cell diseases using anti-germline antibody binding agents
GB0819720D0 (en) * 2008-10-28 2008-12-03 Univ Birmingham Methods and products

Also Published As

Publication number Publication date
RU2012120620A (ru) 2013-11-27
AU2010310562A1 (en) 2012-06-07
EP2490721A4 (en) 2013-05-15
WO2011050259A1 (en) 2011-04-28
US20110097344A1 (en) 2011-04-28
CA2778158A1 (en) 2011-04-28
US20150153357A1 (en) 2015-06-04
TW201125582A (en) 2011-08-01
EP2490721A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
AR078734A1 (es) Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones
Piekut et al. Infectious agents and Alzheimer's disease
Amini-Khoei et al. On the role of corticosterone in behavioral disorders, microbiota composition alteration and neuroimmune response in adult male mice subjected to maternal separation stress
Barnum et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro® 1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats
Lana et al. An overview on the differential interplay among neurons–astrocytes–microglia in CA1 and CA3 hippocampus in hypoxia/ischemia
Bueno et al. Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases
US9598495B2 (en) Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
Ha et al. Human adipose-derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA-induced autism mouse model
Dixit et al. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens
CA2946511C (en) Compositions and methods for treating cytokine-related disorders
RU2015145033A (ru) Композиции и способы для лечения иммунодефицита
EA201171199A1 (ru) Способ очистки рекомбинантного фсг
Zhang et al. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
US20200216518A1 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
EP1597271B1 (de) Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung
Figueiredo et al. The neuropeptide PACAP alleviates T. gondii infection-induced neuroinflammation and neuronal impairment
Jones et al. Review of animal models of neuromyelitis optica
Gay Bacterial transportable toxins of the nasopharyngeal microbiota in multiple sclerosis. Nose-to-brain direct
Lovreček et al. A century of antivenom
León et al. Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
JP2021517561A (ja) 神経学的障害及び他の障害を治療するための組成物及び方法
Vargas-Rodríguez et al. Novel Therapeutic Opportunities for Neurodegenerative Diseases with Mesenchymal Stem Cells: The Focus on Modulating the Blood-Brain Barrier
CN106890192A (zh) 一种增强记忆的源自血浆的混合物及其制备方法和应用
KR20130009161A (ko) 줄기세포 배양액의 유효성분을 이용한 아토피성 피부염의 치료 및 증상 완화용 조성물

Legal Events

Date Code Title Description
FB Suspension of granting procedure